
A protein-based, liquid biopsy screening test demonstrated greater than 90% sensitivity and specificity for early breast cancer detection.
Justin Drake, PhD, is chief science officer at Astrin Biosciences.

A protein-based, liquid biopsy screening test demonstrated greater than 90% sensitivity and specificity for early breast cancer detection.